STOCK TITAN
  1. Home
  2. News
  3. PRTA

Prothena Corporation plc - PRTA STOCK NEWS

Welcome to our dedicated news page for Prothena Corporation plc (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena Corporation plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Prothena Corporation plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Prothena Corporation plc's position in the market.

News
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
Rhea-AI Summary
Prothena plc (NASDAQ:PRTA) announces the publication on the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab, a potential anti-amyloid treatment for AL amyloidosis. The publication in Leukemia & Lymphoma highlights birtamimab's ability to clear amyloid deposits in vital organs, showing a significant survival benefit in patients with Mayo Stage IV AL amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
News
Prothena to Participate in Upcoming Healthcare Conferences
Rhea-AI Summary
Prothena Corporation plc (PRTA) announced senior management's participation in upcoming investor conferences. The company will be present at Leerink Partners Global Biopharma Conference on March 12 and Jefferies Biotech on the Bay Summit on March 13. A webcast of the fireside chat will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
conferences
-
News
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Rhea-AI Summary
Prothena Corporation plc (PRTA) appoints David Ford as Chief People Officer to drive human resources strategy and company growth. Ford brings over 25 years of HR experience, transitioning Prothena to a commercially successful entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
management
News
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Rhea-AI Summary
Prothena Corporation plc (NASDAQ:PRTA) appoints Daniel G. Welch as an independent director and Chair Designate. The company plans a transition in leadership with Dr. Lars Ekman stepping down as Chair. Mr. Welch's vast industry experience aims to guide Prothena through a transformative phase in advancing neurodegenerative and rare peripheral amyloid disease therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
management
-
News
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
Rhea-AI Summary
Prothena Corporation plc (PRTA) reported a net loss of $67.5 million for Q4 2023 and $147.0 million for the full year. The company expects to end 2024 with approximately $405 million in cash. Significant advancements were made in the Alzheimer’s disease portfolio, with promising Phase 1 clinical trial data for PRX012 and FDA clearances for PRX123. Prothena also received a $55 million milestone payment from Bristol Myers Squibb. The company's financials show an increase in R&D and G&A expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
earnings
-
News
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
Rhea-AI Summary
Prothena Corporation plc (PRTA) will report its Q4 and full year 2023 financial results on February 15, 2024, followed by a live audio conference call. The call will be available via the Company's website and a replay will be accessible for at least 90 days. Dial-in information for accessing the call and the replay is provided in the announcement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
conferences earnings
News
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Rhea-AI Summary
Prothena Corporation plc (PRTA) provided a business update on its late-stage clinical biotechnology programs. The company remains well financed with approximately $621 million in cash, cash equivalents, and restricted cash at year end 2023. Key updates include progress on PRX012 and PRX123 for Alzheimer’s disease, and on birtamimab for AL amyloidosis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.23%
Tags
none
-
News
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Prothena Corporation reported financial results for Q3 and first nine months of 2023. Net cash provided by operating and investing activities was $9.1 million in Q3 and net cash used was $84.1 million for the first nine months. Quarter-end cash position was $673.1 million. Received $55 million payment from Bristol Myers Squibb for exclusive worldwide license to PRX005. Expect to deliver upcoming clinical milestones in the next 15 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
earnings
-
News
Prothena to Report Third Quarter 2023 Financial Results on November 2
Rhea-AI Summary
Prothena Corporation to report Q3 and 9M 2023 financial results on November 2
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
conferences earnings
News
Prothena to Participate in Upcoming Healthcare Conferences
Rhea-AI Summary
Prothena Corporation plc to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
conferences
Stock PRTA logo
Prothena Corporation plc

Nasdaq:PRTA

PRTA Rankings

#2342 Ranked by Market Cap
#4410 Ranked by Stock Gains
N/A Ranked by Dividends

PRTA Stock Data

1.19B
38.28M
12.44%
100.76%
12.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About PRTA

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f